Effects of Losartan on Patients Hospitalized for Acute Coronavirus Disease 2019: A Randomized Controlled Trial

Author:

Tran Karen C1,Asfar Pierre2,Cheng Matthew3,Demiselle Julien4,Singer Joel5,Lee Terry5,Sweet David1,Boyd John6,Walley Keith6,Haljan Greg7,Sharif Omar7,Geri Guillaume8,Auchabie Johann9,Quenot Jean-Pierre10,Lee Todd C11,Tsang Jennifer12,Meziani Ferhat13,Lamontagne Francois14,Dubee Vincent15,Lasocki Sigismond16,Ovakim Daniel17,Wood Gordon17,Turgeon Alexis18,Cohen Yves19,Lebas Eddy20,Goudelin Marine21,Forrest David22,Teale Alastair22,Mira Jean-Paul23,Fowler Robert24,Daneman Nick24,Adhikari Neill K J24,Gousseff Marie25,Leroy Pierre26,Plantefeve Gaetan27,Rispal Patrick28,Courtois Roxane29,Winston Brent30,Reynolds Steve3132,Birks Peter3132,Bienvenu Boris33,Tadie Jean-Marc34,Talarmin Jean-Philippe35,Ansart Severine36,Russell James A6, ,Russell J,Tran K,Cheng M,Asfar P,Demiselle J,Singer J,Mann P,Jain F,Tran K,Donohoe K,Leung V,Lee T,Tran K,Boyd J,Walley K,Tran K,Sweet D,Haljan G,Sharif O,Ovakim D,Wood G,Forrest D,Teale A,Reynolds S,Birk P,Winston B,Fowler R,Dameman N,Adhikari N,Tsang J,Cheng M,Lamontagne F,Turgeon-Fournier A,Asfar ,Demiselle ,Geri D G,Auchabie J,Quenot J P,Meziani F,Dubee V,Lasocki S,Cohen Y,Lebas E,Goudelin M,Mira J P,Gousseff M,Leroy P,Plantefev G,Rispal P,Courtois R,Bievenue B,Tadie J M,Talarmin J P,Ansart S,Yi Tae Won,Levin Adeera

Affiliation:

1. Division of General Internal Medicine, Vancouver General Hospital, University of British Columbia , Vancouver , Canada

2. Service de Médecine Intensive-Réanimation, Centre Hospitalier Universitaire d’Angers , Angers , France

3. McGill’s Interdisciplinary Initiative in Infection and Immunity, Divisions of Infectious Diseases and Medical Microbiology, McGill University Health Centre , Montreal, Quebec , Canada

4. Service de Médecine Intensive-Réanimation, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg , Strasbourg , France

5. Centre for Health Evaluation and Outcome Science, St Paul's Hospital and University of British Columbia , Vancouver , Canada

6. Division of Critical Care Medicine, and Centre for Heart Lung Innovation, St Paul's Hospital , Vancouver , Canada

7. Department of Medicine and Critical Care Medicine, Surrey Memorial Hospital , British Columbia , Canada

8. Service de Médecine Intensive-Réanimation, Assistance Publique–Hôpitaux de Paris Ambroise Paré , Boulogne , France

9. Service de Réanimation Polyvalente, Centre Hospitalier de Cholet

10. Service de Médecine Intensive-Réanimation, Centre Hospitalier Universitaire Dijon , Dijon , France

11. McGill's Interdisciplinary Initiative in Infection and Immunity, McGill University Health Centre , Montreal, Quebec , Canada

12. Niagara Health, McMaster University , St Catherines, Ontario , Canada

13. Service de Médecine Intensive-Réanimation, Nouvel Hôpital Civil Strasbourg , Strasbourg , France

14. Centre Hospitalier Universitaire de Sherbrooke, University of Sherbrooke , Quebec , Canada

15. Service de Maladies Infectieuses, Centre Hospitalier Universitaire d'Angers , Angers , France

16. Service de Réanimation Chirurgicale, Centre Hospitalier Universitaire Angers , Angers , France

17. Royal Jubilee Hospital, Island Health , Victoria, British Columbia

18. Department of Medicine, Centre Hospitalier Universitaire de Québec–Université Laval , Quebec , Canada

19. Service de Médecine Intensive-Réanimation, Assistance Publique–Hôpitaux de Paris Avicenne , Bobigny , France

20. Service de Réanimation Polyvalente, Centre Hospitalier Bretagne-Atlantique , Vannes , France

21. Service de Réanimation Polyvalente, Centre Hospitalier Universitaire Limoges , Limoges , France

22. Department of Medicine, Nanaimo Regional General Hospital , British Columbia , Canada

23. Service de Médecine Intensive-Réanimation, Assistance Publique-Hôpitaux de Paris , Cochin , France

24. Critical Care Medicine, Sunnybrook Health Sciences Centre , Toronto, Ontario , Canada

25. Service de Médecine Interne–Maladies Infectieuses–Hématologie, Centre Hospitalier Bretagne-Atlantique , Vannes , France

26. Service de médecine polyvalente et maladies infectieuses, Centre Hospitalier Melun , Melun , France

27. Service de Réanimation Polyvalente, Centre Hospitalier Argenteuil , France

28. Department of Medicine, Service de médecine interne, Centre Hospitalier Agen , Agen , France

29. Service de Médecine post-urgences–Maladies infectieuses, Centre Hospitalier de Cholet , Cholet , France

30. Departments of Critical Care Medicine, Medicine, and Biochemistry and Molecular Biology, Foothills Medical Centre, University of Calgary , Alberta , Canada

31. Critical Care Medicine, Royal Columbian Hospital , New Westminster, British Columbia , Canada

32. Department of Medicine, Simon Fraser University , Surrey, British Columbia , Canada

33. Service de médecine interne, Hôpital St Joseph , Marseille , France

34. Service de Médecine Intensive-Réanimation et de Maladies Infectieuses, Centre Hospitalier Universitaire de Rennes , Rennes , France

35. Service de médecine interne, maladies du sang et infectiologie, Centre Hospitalier de Quimper , Quimper , France

36. Service de Maladies Infectieuses, Centre Hospitalier Régional Universitaire Brest , Brest , France

Abstract

Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) down-regulates angiotensin-converting enzyme 2, potentially increasing angiotensin II. We hypothesized that losartan compared to usual care decreases mortality and is safe in patients hospitalized with coronavirus disease 2019 (COVID-19). We aimed to evaluate the effect of losartan versus usual care on 28-day mortality in patients hospitalized for acute COVID-19. Methods Eligibility criteria included adults admitted for acute COVID-19. Exclusion criteria were hypotension, hyperkalemia, acute kidney injury, and use of angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors within 7 days. Participants were randomized to losartan 25–100 mg/day orally for the hospital duration or 3 months or the control arm (usual care) in 29 hospitals in Canada and France. The primary outcome was 28-day mortality. Secondary outcomes were hospital mortality, organ support, and serious adverse events (SAEs). Results The trial was stopped early because of a serious safety concern with losartan. In 341 patients, any SAE and hypotension were significantly higher in the losartan versus usual care groups (any SAE: 39.8% vs 27.2%, respectively, P = .01; hypotension: 30.4% vs 15.3%, respectively, P < .001) in both ward and intensive care patients. The 28-day mortality did not differ between losartan (6.5%) versus usual care (5.9%) (odds ratio, 1.11 [95% confidence interval, .47–2.64]; P = .81), nor did organ dysfunction or secondary outcomes. Conclusions Caution is needed in deciding which patients to start or continue using ARBs in patients hospitalized with pneumonia to mitigate risk of hypotension, acute kidney injury, and other side effects. ARBs should not be added to care of patients hospitalized for acute COVID-19. Clinical Trials Registration NCT04606563.

Funder

Canadian Institutes of Health Research

Publisher

Oxford University Press (OUP)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3